Cargando…
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
The efficacy of checkpoint immunotherapy to non-small cell lung cancer (NSCLC) largely depends on the tumor microenvironment (TME). Here, we demonstrate that CCL7 facilitates anti-PD-1 therapy for the Kras(LSL−G12D/+)Tp53(fl/fl) (KP) and the Kras(LSL−G12D/+)Lkb1(fl/fl) (KL) NSCLC mouse models by rec...
Autores principales: | Zhang, Man, Yang, Wei, Wang, Peng, Deng, Yu, Dong, Yu-Ting, Liu, Fang-Fang, Huang, Rui, Zhang, Peng, Duan, Ya-Qi, Liu, Xin-Dong, Lin, Dandan, Chu, Qian, Zhong, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704643/ https://www.ncbi.nlm.nih.gov/pubmed/33257678 http://dx.doi.org/10.1038/s41467-020-19973-6 |
Ejemplares similares
-
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
por: Saddawi-Konefka, Robert, et al.
Publicado: (2022) -
Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy
por: Zhan, Jing, et al.
Publicado: (2023) -
CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis
por: Qian, Bin-Zhi, et al.
Publicado: (2011) -
Conventional type 1 dendritic cells (cDC1) in cancer immunity
por: Liu, Peng, et al.
Publicado: (2023) -
Augmenting E Protein Activity Impairs cDC2 Differentiation at the Pre-cDC Stage
por: Bajana, Sandra, et al.
Publicado: (2020)